AEON Biopharma names former FDA neuroscience leader Paul Lee acting chief regulatory officer

Reuters2026/08/24 12:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AEON Biopharma named Paul Lee as acting chief regulatory officer through Clintrex Research.
Lee previously served at the FDA as deputy director of the Office of Neuroscience.
He also led the FDA’s Division of Neurology 2.
Role includes leading regulatory strategy for ABP-450, a biosimilar to BOTOX for therapeutic use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AEON Biopharma names former FDA neuroscience leader Paul Lee acting chief regulatory officer

You may also like

Crypto prices